The estimated Net Worth of James C Clemmer is at least $8.24 Milión dollars as of 17 July 2024. Mr. Clemmer owns over 56,279 units of Angiodynamic Inc stock worth over $5,122,115 and over the last 9 years he sold ANGO stock worth over $0. In addition, he makes $3,116,630 as President, Chief Executive Officer a Director at Angiodynamic Inc.
Sign up
Mr. Clemmer ANGO stock SEC Form 4 insiders trading
James has made over 11 trades of the Angiodynamic Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 56,279 units of ANGO stock worth $417,590 on 17 July 2024.
The largest trade he's ever made was exercising 200,000 units of Angiodynamic Inc stock on 12 July 2019 worth over $1,484,000. On average, James trades about 9,830 units every 57 days since 2015. As of 17 July 2024 he still owns at least 690,312 units of Angiodynamic Inc stock.
You can see the complete history of Mr. Clemmer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Clemmer biography
James C. Clemmer serves as President, Chief Executive Officer, Director of the Company. Prior to joining AngioDynamics, Mr. Clemmer served as President of the $1.8 billion medical supplies segment at Covidien plc. where he directed the strategic and day-to-day operations for global business divisions that collectively manufactured 23 different product categories. In addition, he managed global manufacturing, research and development, operational excellence, business development and all other functions associated with the medical supplies business. Prior to his role at Covidien, Mr. Clemmer served as Group President at Kendall Healthcare, where he managed the U.S. business across five divisions and built the strategic plan for the medical supplies segment before it was spun off from Tyco. Mr. Clemmer began his career at Sage Products, Inc. Mr. Clemmer currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging. Mr. Clemmer is a graduate of the Massachusetts College of Liberal Arts, where he served as interim president from August 2015 until March 2016.
What is the salary of James Clemmer?
As the President, Chief Executive Officer a Director of Angiodynamic Inc, the total compensation of James Clemmer at Angiodynamic Inc is $3,116,630. There are no executives at Angiodynamic Inc getting paid more.
How old is James Clemmer?
James Clemmer is 56, he's been the President, Chief Executive Officer a Director of Angiodynamic Inc since 2016. There are 9 older and 16 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.
What's James Clemmer's mailing address?
James's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.
Insiders trading at Angiodynamic Inc
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman a Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
What does Angiodynamic Inc do?
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
What does Angiodynamic Inc's logo look like?
Complete history of Mr. Clemmer stock trades at Angiodynamic Inc a Lantheus Inc
Angiodynamic Inc executives and stock owners
Angiodynamic Inc executives and other stock owners filed with the SEC include:
-
James Clemmer,
President, Chief Executive Officer, Director -
James C. Clemmer,
CEO, Pres & Director -
Chad Campbell,
Senior Vice President and General Manager, Vascular Access -
Stephen Trowbridge,
Chief Financial Officer, Executive Vice President -
Scott Centea,
Senior Vice President, General Manager, VIT -
Stephen A. Trowbridge,
Exec. VP & CFO -
David Helsel,
Senior Vice President - Global Operations -
Brent Boucher,
Senior Vice President and General Manager, Oncology/Surgery -
David D. Helsel,
Sr. VP of Global Operations and R&D -
Warren G. Nighan,
Sr. VP of Quality & Regulatory Affairs -
Chad T. Campbell,
Sr. VP & GM of Vascular Access Global Bus. Unit -
Howard Donnelly,
Independent Chairman of the Board -
Dennis Meteny,
Independent Director -
Wesley Johnson,
Independent Director -
Eileen Auen,
Independent Director -
Jan Reed,
Independent Director -
Karen Licitra,
Independent Director -
Michael Tarnoff,
Independent Director -
Kim Seabury,
Senior Vice President, Information Technology -
Warren Nighan,
Senior Vice President Quality and Regulatory Affairs -
Benjamin Davis,
Senior Vice President Business Development -
Marna Bronfen-Moore,
Senior Vice President of Human Resources -
Scott Centea,
Sr. VP & GM of Vascular Interventions and Therapies & Peripheral Artery Disease -
Kim L. Seabury,
Sr. VP of Information Technology -
Marna I. Bronfen-Moore,
Sr. VP of HR -
Benjamin H. Davis,
Sr. VP of Bus. Devel. -
Richard C. Rosenzweig,
Sr. VP, Gen. Counsel & Company Sec. -
Capital Partners Gp, Llc Av...,
-
Steve La Porte,
Director -
Jeffrey Gold,
Director -
Michael Greiner,
EVP and CFO -
Sriram Venkataraman,
Director -
Kevin J Gould,
Director -
David F Burgstahler,
Director -
Charles R Greiner,
VP - Global Franchise -
Laura Piccinini,
SVP International -
Stark Richard,
SVP, GM - Oncology -
Robert Arthur Simpson,
SVP/GM, Global Vascular -
David P Meyers,
Director -
Gregory D Casciaro,
Director -
Matthew C Kapusta,
SVP, Business Development -
George W. Iv Bourne,
SVP and CTO -
Stephen Mc Gill,
SVP - General Manager -
Mark T Frost,
EVP and CFO -
John Soto,
VP - OUS Sales -
Lynda M. Wallace,
SVP - Business Development -
Vincent Bucci,
Director -
Scott J. Solano,
Senior Vice Preisdent - CTO -
Robert D Mitchell,
Executive VP and COO -
Shawn P Mc Carthy,
SVP - General Manager -
Robert M Rossell,
VP - Marketing -
Robert E Flaherty,
Director -
William M Appling,
VP - Research -
Brian Kunst,
VP - Regulatory Affairs -
Peter J Graham,
Director -
D Joseph Gersuk,
SVP - CFO -
Paul J Shea,
VP - Sales -
Eamonn P Hobbs,
President and CEO -
Joseph G Gerardi,
VP - CFO -
Alan Panzer,
SVP, GM - Vascular -
Harold Mapes,
VP - Operations -
Daniel Recinella,
VP - Product Development -
Paul S Echenberg,
Director -
Richard Scott Etlinger,
SRVPGLOP -
Charles Thomas Orsatti,
Director -
Joseph Devivo,
President and CEO -
Jan Keltjens,
President & CEO -
Howard S Stern,
Director -
Linda B Stern,
10% owner -
Em Inc Ez,
10% owner -
Richard C Rosenzweig,
SVP and General Counsel -
Dave Helsel,
SVP Global Operations and R&D -
Lorinda Burgess,